EGFR inhibitors: what have we learned from the treatment of lung cancer?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,General Medicine
Link
http://www.nature.com/articles/ncponc0341.pdf
Reference57 articles.
1. Parkin DM et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108
2. Dubey S et al. (2005) Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 10: 282–291
3. Herbst RS et al. (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243–3256
4. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23: 3235–3242
5. Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500
Cited by 73 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. An ultra-performance LC–MS/MS method for determination of JRF103 in human plasma: application in first in-patient study;Bioanalysis;2022-09
2. PTPIP51 inhibits non-small-cell lung cancer by promoting PTEN-mediated EGFR degradation;Life Sciences;2022-05
3. Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma;Immunity, Inflammation and Disease;2020-03-03
4. EGFR mutation;Radiopaedia.org;2019-07-01
5. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma;Oncology Letters;2018-10-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3